Strolll secures £4.3m backed by Innovate UK and IW Capital
This article covers Strolll, a healthtech startup, which has secured £4.3m in a growth funding package from Innovate UK alongside more than £1m of private investment led by IW Capital. The funding will support clinical validation and new product development to deliver augmented reality neurorehabilitation for hospital and home use, targeting patients with neurological conditions and clinicians involved in rehabilitation.
Strolll, a healthtech startup, has secured £4.3m in a growth funding round from Innovate UK — a £3.6m innovation loan plus a £700k Growth Catalyst Investor Partnerships (GCIP) award — alongside more than £1m of private investment led by IW Capital, with participation from Cleveland Clinic and Future Planet Capital Regional. The package will pay for clinical validation work and new product development aimed at delivering augmented reality neurorehabilitation in hospitals and at home.
Why it matters
Demand for rehabilitation is rising as populations age and the prevalence of neurological disorders grows. The World Health Organization estimates that more than one in three people worldwide are affected by neurological conditions, creating pressure on health services and on patients to access ongoing therapy. Strolll’s combination of automated assessment tools and AR-delivered therapy targets two persistent bottlenecks: clinical validation of digital assessments and delivering early, accessible therapy to bed-bound or home patients without adding to clinical workload.
Inside the product
Strolll’s platform runs on off-the-shelf augmented reality glasses and is described as a software as a medical device. The company says its clinically proven and patented approach blends digital content with the real world to support neurorehabilitation in clinic and at home. Two projects feature in the funding:
-
StrolllAssessment: an AI-driven system intended to automate the clinical validation of digital neuro-motor assessments. The Innovate UK innovation loan will fund this work and a fully equipped biomechanics lab at Strolll’s Stafford office. The lab is designed to replicate real-world rehabilitation settings so multiple validation studies can run in parallel, which the company says could shorten validation cycles from years to months while maintaining standards compliance.
-
StrolllAcute: funded via the £700k GCIP award alongside private capital, this is a bedside-first AR rehabilitation system for acute, bed-bound patients. The product aims to enable earlier therapeutic intervention without changing ward workflows or increasing staff burden.
Who are the investors?
Innovate UK is the public funder behind the £3.6m innovation loan and £700k GCIP award that form the core of the announced package. Private investment topping more than £1m is led by IW Capital, with participation from Cleveland Clinic — a major US healthcare system — and Future Planet Capital Regional.
In the announcement, Isobel Egemole, Investor at IW Capital, said:
Since our initial investment, Strolll has continued to make strong progress in developing technology that addresses clear challenges within physiotherapy and neurorehabilitation. We're pleased to continue backing Strolll as it enters its next phase of growth, and we look forward to seeing further expansion of its technology platform to improve patient access and outcomes.
In the announcement, Scott O'Brien, Chief Investment Officer at Innovate UK, said:
Across two innovations, Strolll has secured Innovate UK backing because it has proven both its technical excellence and a credible route to commercial success. De-risking later stage innovation through debt finance while providing grant alongside private capital demonstrates how Innovate UK is committed to providing the right product at the right time to accelerate innovation and fuel catalyse business growth.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
In the announcement, Jorgen Ellis, Co-founder & CEO at Strolll, said:
Our team is committed to revolutionising rehabilitation for those living with neurological disorders. This funding will help us accelerate our mission to increase patient engagement, support progression and help clinicians deliver effective neurorehabilitation to a wider patient population.
Ellis framed the raise as both a technical and operational milestone: building the biomechanics lab and moving automated clinical validation toward a standards-compliant, scalable model are intended to unlock broader NHS and international adoption.
The bigger picture
The deal illustrates how mixed public and private capital is being used to de-risk clinical digital health innovation in the UK: Innovate UK’s blend of debt and grant sits alongside private early-stage investors and a clinical partner. It also reflects investor interest in healthtech solutions that combine AI-driven assessment with pragmatic delivery models — here, AR glasses that can be used in wards, clinics and homes without heavy integration work.
For the wider UK and European healthtech ecosystem, the funding highlights two trends: the push to compress clinical validation timelines for digital medical devices, and the growing role of AR and AI in rehabilitation pathways. If Strolll’s lab and automated validation approach deliver as promised, it could shorten the path to regulatory and clinical adoption for similar digital therapies.
They've invested in Strolll
Get to know these healthtech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 | ||||
 IW Capital( ) IW Capital focuses on investing in UK businesses, enabling investors to benefit ... London  | ||||
 Future Planet Capital Regional( ) | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK